Citations

Clear

391 citation(s) found for "Bi, Chun".

Thirty-Six-Month Multicentre Outcomes of Combined Phacoemulsification and Hydrus Microstent Implantation in Eyes With Normal Tension Glaucoma
Ang, Bryan Chin Hou, Sim, Jackie Jia Lin , Chua, Chun Hau, Khairy, Thomas, Salimi, Ali , Harasymowycz, Paul , Ang, Bryan Chin Hou , Ang, Bryan C H , Salimi, Ali , Betzler, Bjorn Kaijun , Ramanathan, Rajesh, Hong, Ashley Shuen Ying

Mayo Clinic

Journal of Glaucoma | March 26, 2026 | Volume: 35 | Issue: 6 | Pages: 369-376

10.1097/ijg.0000000000002709 | PMID 41934671 Get It

Precis: This retrospective multicentre study of 77 NTG eyes undergoing phacoemulsification and Hydrus implantation showed a sustained reduction in medication burden, while maintaining IOP levels. Complications were rare and nonsight-threatening. Purpose: To evaluate 36-month outcomes of combined phacoemulsification and Hydrus Microstent implantation (Phaco-Hydrus) in eyes with normal tension glaucoma (NTG). Methods: This multicentre retrospective study included 77 NTG eyes from Singapore and Canada that underwent Phaco-Hydrus between 2014 and 2023. Primary outcomes were changes in intraocular pressure (IOP) and medication burden, and cumulative success probabilities from Kaplan-Meier (KM) analyses. Longitudinal changes were analysed using generalized estimating equations. Results: Of 77 eyes, 31 completed 36 months of follow-up. Mean baseline IOP and medications was 13.5±2.5 mm Hg and 1.7±0.9, respectively. No significant reductions in IOP were observed. A sustained reduction in medication use was observed at all follow-up timepoints ( P ≤0.001). At 36 months, medication use decreased by −0.7±0.2 [adjusted mean difference±SE of the mean [SEM]]. Proportion of medication-free eyes increased from 7.8% (n=6/77) at baseline to 45.2% (n=14/31) at 36 months. Cumulative success probabilities varied widely based on definitions. When defined as a decrease in ≥1 medication from baseline without an increase in IOP, or IOP ≤15 mm Hg and reduced ≥20% from baseline while medication-free, and no additional laser or incisional glaucoma surgery, this was 40.7% at 36 months. No visual field mean deviation progression was detected. Adverse events were infrequent and nonsight-threatening. Conclusion: In eyes with NTG, Phaco-Hydrus may offer a greater role in medication reduction or achieving a medication-free status over 36 months, rather than absolute IOP reduction.
Non-headache symptoms and rapid number naming task scores during migraine phases including headache, prodrome, postdrome and non-migraine headache attacks versus interictal state: A longitudinal cohort study
VanderPluym, Juliana H. , Patel, Rahul , Starling, Amaal J. , Girardo, Marlene , Chiang, Chia‐Chun , Chiang, Chia-Chun , Starling, Amaal J , VanderPluym, Juliana

Mayo Clinic

Cephalalgia Reports | March 25, 2026 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/25158163261436784 Get It

Aim To determine whether there is a difference in the time to complete a rapid number naming task during the interictal state compared to prodrome, migraine headache, postdrome phases of migraine and non-migraine headache, and characterize non-headache symptoms experienced during these phases. Methods This prospective longitudinal cohort study evaluated 30 adults with migraine with or without aura who completed diary entries and a timed rapid number naming task at least three times daily for up to four months from October 2020 to July 2022 at a tertiary headache center. Diary entries included self-report of current migraine phase (having a migraine headache, non-migraine headache, prodrome, postdrome, or interictal baseline) and detailed symptoms experienced. The outcome of interest for the timed rapid number naming task was the time to complete the task with zero errors. Results Compared to the interictal baseline, the time with zero errors for the rapid number naming task was significantly slower during the prodrome (median (Q1, Q3) 1.0 s slower (0.4, 2.9), p -value 0.010), migraine headache (median (Q1, Q3) 3.8 s slower (2.6, 7.5), p -value <0.001), and postdrome (median (Q1, Q3) 0.9 s slower (0.2, 2.1), p -value 0.011) phases of migraine, and non-migraine headache attacks (median (Q1, Q3) 1.2 s slower (0.1, 3.1), p -value 0.006). For those with migraine with aura (N = 15), the time with zero errors was significantly slower during all phases compared to interictal phase. For those with migraine without aura (N = 15), the time with zero errors was significantly slower only during the migraine headache, but not other phases compared to the interictal phase. The top 5 most reported non-headache symptoms during any phase of migraine and non-migraine headache attacks included fatigue, neck stiffness, light sensitivity, blurred vision/vision changes, and difficulty concentrating. Conclusions Among the overall participant cohort, the time with zero errors to complete a rapid number naming task was significantly slower during all ictal phases compared to interictal phase. This was also the case in the migraine with aura cohort but in the migraine without aura cohort there was only a significant difference during the migraine headache phase versus interictal phase. There is overlap in non-headache symptoms between the prodrome, migraine headache, postdrome, and non-migraine headache phases, which may make distinguishing between these phases difficult. Combining subjective data, such as symptom diaries, with objective measures, such as rapid number naming tasks, may allow for more refined assessment of migraine phases and distinguishing migraine from non-migraine headache attacks.
Decoding the tumor microenvironmental program behind HCC recurrence after incomplete radiofrequency ablation
Povero, Davide , Wong, Chun-ming, Povero, Davide

Mayo Clinic

Hepatology | March 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001746 | PMID 41849749 Get It

Genotype-phenotype heterogeneity among patients with lipodystrophy harboring rare POLD1 variants
Hoff, Fieke W. , Xing, Chao, Huang, Chun-Yuan , Simha, Vinaya , Brown, Rebecca J. , Garg, Abhimanyu , Xing, Chao , Xing, Chao , Brown, Rebecca J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | February 24, 2026 | Volume: 111 | Issue: 8 | Pages: 2378-2388

10.1210/clinem/dgag079 | PMID 41742372 Get It

Abstract Context Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy (MDPL) syndrome is a rare, autosomal dominant disorder due to pathogenic heterozygous variants in POLD1. Clinical features of MDPL vary between patients; however, there is no previously reported genotype-phenotype association. Objective This work reports 14 new patients with lipodystrophy due to POLD1 variants and compares phenotypic differences between those with p.Ser605del and missense variants. Methods Genetic sequencing was performed on DNA of 14 patients for POLD1 variants, including exome (n = 10), genome (n = 1), and candidate gene (n = 3) sequencing. Comparisons of demographic, clinical features, and metabolic complications between carriers of POLD1 p.Ser605del and missense variants in our cases and those reported in the literature were made using the Fisher exact test for categorical variables and the t test for continuous variables. Results A total of 9 different POLD1 variants were identified in our patients, including 3 novel variants: p.Asp25Glufs*16, p.Arg507His, and p.Trp781Cys. Compared to individuals with missense variants (n = 15), those with the p.Ser605del (n = 26) POLD1 variant had significantly increased prevalence of mandibular hypoplasia (57% vs 100%, respectively; P = .015), small mouth (36% vs 100%, respectively; P = .015), crowded teeth (44% vs 91%, respectively; P = .046), and hypogonadism in male patients (0% vs 92%, respectively; P = .046). There were no differences in the prevalence of metabolic complications, such as diabetes, hypertriglyceridemia, and hepatic steatosis, in the two groups. Conclusion Individuals with the heterozygous POLD1 p.Ser605del variant had typical MDPL with more severe phenotype compared to those with missense variants with atypical MDPL.
Higher artificial intelligence‐ ECG atrial fibrillation prediction model output and estimated physiologic aging predict higher risk of adverse vascular events in patients with migraine
Yang, Ping‐Hao , Zhang, Nan, Chao, Chieh‐Ju, Lopez‐Jimenez, Francisco, Mangold, Kathryn, Attia, I Z, Friedman, Paul A, Noseworthy, Peter A., Tietjen, Gretchen E. , Chiang, Chia‐Chun , Chiang, Chia-Chun , Chao, Chieh‐Ju , López-Jiménez, Francisco , Attia, Zachi I. , Friedman, Paul A. , Noseworthy, Peter A.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 21, 2026 | Volume: 66 | Issue: 6 | Pages: 1263-1274

10.1111/head.70062 | PMID 41721210 Get It

Abstract Objective To investigate the ability of artificial intelligence‐enabled electrocardiogram (AI‐ECG) atrial fibrillation (AF) prediction model output and delta age, defined as AI‐estimated age minus chronological age, to predict adverse vascular outcomes in patients with migraine. Background Migraine, especially migraine with aura, is associated with an increased risk of cardiovascular events. Using normal sinus rhythm ECG, our institution has developed AI‐ECG models that predict the probability of AF and estimate patients' age, and from that, delta age (estimated age minus actual age) has been shown to reflect cardiovascular health and physiologic aging. Methods We conducted a retrospective cohort study that included adult patients with migraine who had at least one digital, standard 12‐lead ECG from 2000 to 2020 at any Mayo Clinic site. The first normal sinus rhythm ECG was defined as the index ECG, and those with adverse vascular events or AF prior to, or within 3 days after, index ECG were excluded. AI‐ECG AF prediction model output and delta age were obtained from the index ECG. The primary outcome was a composite endpoint of adverse vascular events that included acute myocardial infarction, acute ischemic stroke, venous thromboembolism, and death. New‐onset AF was also recorded as a secondary outcome. Results A total of 29,928 patients were included. The mean age was 44.3 ± 14.5 years, and the median follow‐up time was 54 months. During the study period, 4662 (15.6%) patients had adverse vascular events, and 1384 (4.6%) patients developed new‐onset AF. A higher AF prediction model output was associated with a higher risk of adverse vascular outcomes (adjusted hazard ratio [aHR]:1.15 [95% confidence interval: 1.12 to 1.18] for every 10% increase in prediction model output), as was a larger delta age (aHR:1.16 [1.12 to 1.21] for every 10‐year increase in delta age). Moreover, AI‐ECG AF prediction model outputs of ≥1% (aHR: 1.45 [1.36 to 1.54]) and delta age ≥−1 years (aHR: 1.09 [1.02 to 1.16]) were found to be the optimal cutoffs to dichotomize patients into high‐risk and low‐risk groups for adverse vascular events. Higher AI‐ECG AF prediction model output at baseline also predicted a higher likelihood of having new‐onset AF during the study period (aHR: 1.31 [1.26 to 1.37]), and the development of new‐onset AF was associated with a higher risk of adverse vascular events (aHR: 2.43 [2.17 to 2.73]). Conclusions For patients with migraine, a higher AI‐ECG AF prediction model output and delta age are predictive of adverse vascular outcomes. A higher AF prediction model output is also predictive of future AF development. Furthermore, we identified the cutoffs for both AI‐ECG models that can distinguish patients between high‐ and low‐risk groups. Our results showed that AI‐ECG models could inform clinical practice and identify patients with migraine at risk for future adverse vascular events.
ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment
Song, Nuozi , Chen, Siqi, Wang, Lei , Dang, Jessica, Singh, Stephanie, Yang, Lu, Rosen, Steven T., Wang, Yingyu, Chen, Chun‐Wei D., Zhang, Cheng, Feng, Mingye , Chen, Chun‐Wei , Feng, Mingye , Chen, Chun-Wei , Dang, Jessica, Cao, Xu , Wang, Jinhui , Rosen, Steven T.

Mayo Clinic

Advanced Science | February 3, 2026 | Volume: 13 | Issue: 20 | Pages: No page available

10.1002/advs.202513672 | PMID 41632816 Get It

ABSTRACT Tumorigenesis and metastasis are frequently attributed to the intricate interplay between cancer cells and the tumor microenvironment (TME). Comprehending the mechanisms and key regulators of cancer‐immune crosstalk in the TME is imperative for developing efficacious immunotherapy. Through a series of in vivo CRISPR screens, we identified tumor‐intrinsic ITGB1 as a critical regulator of triple‐negative breast cancer (TNBC) development and deciphered its underlying mechanisms. Tumoral ITGB1 facilitated the establishment of pro‐tumorigenic TME by orchestrating tumor‐associated myeloid populations. Suppressing ITGB1 favored the enrichment of anti‐tumorigenic myeloid cells and enhanced infiltration of CD4 and CD8 T cells, culminating in superior antitumor effects. CRISPR scanning pinpointed a previously unrecognized functional domain essential for ITGB1's pro‐tumorigenic activity. This domain is distinct from all known ligand‐binding sites in ITGB1. An antibody capable of sterically blocking this domain significantly impaired TNBC progression. These findings position tumoral ITGB1 as a promising therapeutic target for reprogramming the TME from a pro‐ to an anti‐tumorigenic state, thereby effectively inhibiting TNBC development. Our study uncovers a novel mechanism of TNBC development and provides a unique therapeutic strategy for targeting ITGB1 in TNBC treatment.
Safety and efficacy of intracardiac echocardiography in atrial fibrillation ablation: a meta-analysis
Karakasis, Paschalis , Tzeis, Stylianos , Pamporis, Konstantinos , Vlachos, Konstantinos , Siontis, Konstantinos C, Antoniadis, Antonios P , Bénali, Karim , Theofilis, Panagiotis null, Tsiachris, Dimitris , Chun, Julian, Jaïs, Pierre , Fragakis, Nikolaos, Karakasis, Paschalis , Pamporis, Konstantinos , Antoniadis, Antonios P. , Siontis, Konstantinos C , Theofilis, Panagiotis , Tsiachris, Dimitrios , Chun, Julian K R , Fragakis, Nikolaos , Tzeis, Stylianos , Siontis, Konstantinos C. , Benali, Karim , Jaı̈s, Pierre

Mayo Clinic

Europace | January 8, 2026 | Volume: 28 | Issue: 2 | Pages: No page available

10.1093/europace/euag002 | PMID 41563860 Get It

Abstract Aims Intracardiac echocardiography (ICE) is increasingly incorporated into atrial fibrillation (AF) ablation workflows, enabling real-time anatomic guidance and procedural precision. Nevertheless, ICE utilization shows substantial geographic variability, and its clinical benefit remains incompletely understood. This meta-analysis evaluated the efficacy, safety, and procedural performance of ICE-guided vs. non-ICE-guided AF ablation. Methods and results MEDLINE, the Cochrane Library, and Scopus were systematically searched through 3 August 2025. Three reviewers independently performed study selection, data extraction, and risk-of-bias assessment. Random-effects models were used to pool data from 44 AF ablation studies comprising 482 043 patients. ICE guidance was associated with lower odds of any complication (OR 0.69; 95% CI 0.53–0.89), including significant reductions in cardiac tamponade (OR 0.58; 95% CI 0.53–0.62) and mortality (OR 0.21; 95% CI 0.16–0.27). ICE-guided ablation was also associated with shorter total procedure and fluoroscopy times, reduced radiation exposure, and lower contrast agent utilization. Atrial tachyarrhythmia (AT) recurrence did not differ between groups (OR 0.92; 95% CI 0.79–1.06). However, ICE use was associated with higher odds of first-pass pulmonary vein isolation (OR 1.62; 95% CI 1.09–2.41) and successful isolation of all pulmonary veins at the end of the procedure (OR 2.12; 95% CI 1.37–3.27), and lower odds of repeat ablation (OR 0.65; 95% CI 0.59–0.72). Conclusion ICE-guided AF ablation is associated with superior procedural safety and efficiency and a similar risk of AT recurrence compared to non-ICE-guided approaches.
Physeal Allograft Transfer for Physeal Bars: A Safety and Feasibility Study in a Domestic Swine Model
Korpershoek, J. V., Chen, C., Nagelli, C. V., Lydon, K. L., Floren, M. L., Saris, D. B. F., Larson, A. N., Milbrandt, T. A., Korpershoek, Jasmijn V. , Chen, Chun‐Ho , Korpershoek, Jasmijn V , Chen, Chunho , Nagelli, Christopher V. , Lydon, Katherine L. , Floren, Michael L. , Saris, Daniël B.F.

Mayo Clinic

Journal of Orthopaedic Research | January 4, 2026 | Volume: 44 | Issue: 1 | Pages: No page available

10.1002/jor.70133 | PMID 41485130 Get It

ABSTRACT Premature physeal closure occurs following trauma, cancer, or infection. Current treatments have poor success rates. With recent pediatric donor tissue availability, physeal allograft transfer (PAT) can now be considered. The purpose of this study was to study the safety and feasibility of PAT in a large animal model. The aim of this study is to gather foundational data to inform future studies into the efficacy of PAT. Physeal defects were created in the distal femur of nine female domestic swine and treated with PAT from two male donor pigs, cementation, or bone autograft. Viability was assessed. After 3 months, physes were visualized using CT and MRI. Integration, tissue composition, donor DNA presence, and microscopic appearance were evaluated. Physeal allografts demonstrated 93% viability after procurement and preservation. All animals reached the 3‐months study endpoint without gross deformations. No physeal bars formed in any group. Cystic changes were seen in experimental and control femurs. All groups showed disorganized tissue architecture without growth plate recapitulation. High allografts viability and structural integrity after procurement support the potential of this treatment. Although no gross deformities were found, transferred physes demonstrate poor integration and incomplete repair. The lack of physeal bar formation in the control group limits the reliability of the animal model for studying physeal allograft transfer. Lastly, this study was designed as a feasibility study and lacks power to compare treatment effects statistically. The efficacy of PAT for preventing growth arrest remains undetermined.
A novel out-of-frame CREBBP::TRAP1 fusion in malignant intracerebral nerve sheath tumor
Chakraborty, Debopriya, Donnelly, Liam, Lefferts, Joel A. , Green, Donald C, Shannon, Patrick M., Mm, Quezado, Abdullaev, Ziedulla , Aldape, Kenneth D, Lin, Chun‐Chieh , Shannon, Patrick M, Quezado, M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnen/nlaf162 | PMID 41769772 Get It

Estrogen exposure from modern contraceptives and vascular risk in women with migraine: A nationwide electronic medical record database study
Ihara, Keiko , Pike, C. William , Hui, Gavin , Jackson, Michael L. , Tietjen, Gretchen E. , Chiang, Chia‐Chun , Chiang, Chia-Chun , Gombar, Saurabh , Callahan, Alison

Mayo Clinic

Cephalalgia | December 17, 2025 | Volume: 45 | Issue: 12 | Pages: No page available

10.1177/03331024251404924 | PMID 41406065 Get It

Background Many guidelines list migraine with aura (MwA) as a contraindication to estrogen-containing combined hormonal contraceptives (CHCs) due to vascular risks. However, current evidence is based on small sample studies with potential influence by confounding factors. Additionally, few studies have examined the vascular risk associated with modern CHCs with lower dose estrogen, particularly in relation to aura status. The present study aims to investigate the vascular risk of modern CHCs in women with migraine with and without aura. Methods We used a de-identified electronic medical record database with 120 million patients across multiple health systems in the United States of America. We included female patients aged 18–45 years who received a migraine diagnosis code, had at least three office visits within three years, and were prescribed at least one migraine-specific medication within 6 months following the first outpatient visit. All data after 2010 were included. Patients with prior cardiovascular events were excluded. Our composite endpoint consisted of acute ischemic stroke, acute myocardial infarction, deep vein thrombosis/pulmonary embolism and intravenous thrombolytic administration. We stratified our analysis according to CHC exposure and aura status and compared the incidence of the endpoint with high-dimensional propensity score-matching between CHC users and non-users in (i) the overall cohort, (ii) MwA and (iii) migraine without aura (MwoA); between MwA and MwoA in (iv) patients prescribed CHCs; and in (v) those without CHC prescriptions. Results We included 5535 patients who received CHC prescriptions and 21,520 who did not. 114 (2.06%) of CHC users and 547 (2.54%) of CHC non-users had at least one vascular event. With propensity score-matched comparison, the composite endpoint did not significantly differ between CHC and non-CHC in the overall migraine group, those with MwA and the MwoA group. In those prescribed CHC, MwA and MwoA did not differ in all the outcomes. For CHC non-users, MwA was associated with a higher incidence of acute ischemic stroke (hazard ratio = 2.45; 95% confidence interval = 1.58–3.78; p < 0.001; n = 6201 in each group) and the composite endpoint (hazard ratio = 1.34; 95% confidence interval = 1.08–1.67; p = 0.008). Conclusions Our real-world study showed that exposure to modern CHC was not associated with a significant increase in vascular risk in women aged 18–45 years with migraine, MwA or MwoA who have no prior cardiovascular events. However, in those who never received CHC, MwA was associated with higher vascular risks compared to MwoA. While limitations exist using large scale electronic medical record databases for analysis, our results suggest that carefully designed prospective studies should be conducted to reassess the vascular risk associated with CHC use in women with migraine, especially MwA.